Pre-made Siplizumab benchmark antibody (Whole mAb, anti-CD2 therapeutic antibody, Anti-LFA-2/SRBC/T11 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-INN-992

Anti-CD2 therapeutic antibody (Pre-made Siplizumab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Siplizumab (MEDI-57) is a novel monoclonal antibody with a human IgG1, kappa directed to CD2. The agent has shown potent immunomodulatory effects, selectively suppressing the function of T and NK cells, and is currently being tested as a possible treatment for psoriasis and in the prevention of graft-versus-host disease.[1]

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-INN-992-1mg 1mg 3090
GMP-Bios-INN-992-10mg 10mg Inquiry
GMP-Bios-INN-992-100mg 100mg Inquiry
GMP-Bios-INN-992-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Pre-Made Siplizumab Biosimilar, Whole Mab, Anti-Cd2 Antibody: Anti-LFA-2/SRBC/T11 therapeutic antibody
INN Name Siplizumab
FormatWhole mAb
Species Reactivityhuman
CH1 IsotypeIgG1 - kappa
VD LCIgG1 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
CompaniesBioTransplant (Charlestown MA USA) / MedImmune (Gaithersburg MD USA) / AstraZeneca (London UK)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech0